J Korean Soc Pediatr Endocrinol.  1997 Mar;2(1):53-59.

Change of Serum IGF-I and IGFBP-3 Concentration During Induction Chemotherapy in Children with Acute Lymphocytic Leukemia

Abstract

PURPOSE
The most important regulatory factor for IGF-I and IGFBP-3 known so far GH and food intake. Poor nutrition in children with acute lymphocytic leukemia(ALL) increase morbidity during treatment. The aim of this study was to assess the changes of serum IGF-I and IGFBP-3 concentration during induction chemotherapy in 13 children with acute lymphocytic leukemia.
METHODS
13 children aged between 1.6 and 13.5 years with ALL were studied the changes of serum IGF-I and IGFBP-3 concentration before, at 2 and 4 weeks after induction chemotherapy. Serum IGF-I and IGFBP-3 were measured using radioimmunoassay.
Results
: 1) Mean serum IGF-I and IGFBP-3 concentration before induction chemotherapy in ALL patient was significantly lower than the those of normal control(p<0.05). 2) Mean serum IGF-I and IGFBP-3 concentration at 2 weeks of induction chemotherapy were significantly higher than the those of the basal levels (p<0.05). 3) Mean serum IGF-I and IGFBP-3 concentration at 4 weeks after induction chemotherapy were significantly higher than the those of the basal levels (p<0.05).
Conclusion
: Concentration of serum IGF-I and IGFBP-3 in patients with ALL were significantly increased during induction chemotherapy. These results are probably related to improvement of nutritional status following induction chemotherapy.

Keyword

IGF-I; IGFBP-3 and Acute lymphocytic leukemia

MeSH Terms

Child*
Eating
Humans
Induction Chemotherapy*
Insulin-Like Growth Factor Binding Protein 3*
Insulin-Like Growth Factor I*
Nutritional Status
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Radioimmunoassay
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Full Text Links
  • JKSPE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr